SCHEMBL3247616

SCHEMBL3247616

Nc1ccc(Cl)cc1Cc1ccccc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPO P05164 2/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
HPGD P15428 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ADCY10 Q96PN6 1/20 0.42
TAAR1 Q96RJ0 1/20 0.41
PKM P14618 1/20 0.41
CYP3A4 P08684 4/20 0.41
ALOX15 P16050 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TSHR P16473 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
PLA2G1B P04054 1/20 0.41
CYP2D6 P10635 1/20 0.41
ATG4B Q9Y4P1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11777239 0.83 MPO (0.44) MPOMEN1KMT2AALDH1A1HPGD
SCHEMBL3264814 0.83 MPO (0.47) MPOMEN1KMT2AALDH1A1CYP2C9
SCHEMBL3251975 0.82 CYP3A4 (0.47) MPOMEN1KMT2AALDH1A1HPGD
SCHEMBL22231837 0.80 CYP1A2 (0.44) MPOMEN1KMT2AALDH1A1CYP1A2
SCHEMBL6339844 0.79 ALOX15 (0.58) MEN1KMT2AALDH1A1CYP2C9CYP2C19
SCHEMBL28870145 0.79 MPO (0.41) MPOADCY10TAAR1CYP3A4ALOX15
SCHEMBL10515673 0.79 TAAR1 (0.52) MPOMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL4768466 0.79 TBXA2R (0.50) MEN1KMT2AALDH1A1CYP1A2CYP2C9
SCHEMBL5006969 0.77 CYP3A4 (0.62) MPOMEN1KMT2AALDH1A1CYP1A2
SCHEMBL3254694 0.76 CYP3A4 (0.52) MEN1KMT2AALDH1A1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
EP-1776347-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Sanofi-Aventis (FR) 2007-04-25 EP disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 WO disclosed
US-5792874-A Process for the manufacture of 8-chloro-6-(2-flourophenyl)-1-methyl-4H-imidazo 1,5A! 1,4!benzodiazepine (midazolam) RANBAXY LABORATORIES, LTD. (IN) 1998-08-11 US disclosed
US-5756729-A Process for the manufacture of 8-chloro-6 (2-fluorophenyl)-1 methyl-4H-imidazo 1,5a! 1,4! benzodiazepine (midazolam) RANBAXY LABORATORIES, LTD. (IN) 1998-05-26 US disclosed
EP-0835874-A2 A process for the manufacture of 8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo (1,5a)(1,4) benzodiazepine (midazolam) RANBAXY LABORATORIES, LTD. (IN) 1998-04-15 EP disclosed
US-4281142-A Imidazolecarboxaldehydes HOFFMANN-LA ROCHE INC. (US) 1981-07-28 US disclosed
EP-0017181-A1 Process for the production of imidazobenzodiazepine derivatives, and intermediates for their production F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1980-10-15 EP disclosed
US-4194049-A 2-[[2-Methyl-1-[2-benzoyl(or benzyl)phenyl]-1H-imidazol-5-yl]methyl]-1H-isoindole-1,3(2H)-diones HOFFMANN-LA ROCHE INC. (US) 1980-03-18 US disclosed
US-3992400-A 1-(α-Phenyl-o-tolyl)imidazoles THE UPJOHN COMPANY (US) 1976-11-16 US disclosed
US-3941803-A 2-(Imidazol-1-yl)benzophenones THE UPJOHN COMPANY (US) 1976-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 MPO 1260/4885MEN1 375/4885KMT2A 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.